 Randall Meacham
Concepts (364)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infertility, Male | 13 | 2013 | 61 | 1.810 |
Why?
| | Ejaculation | 6 | 2006 | 10 | 1.040 |
Why?
| | Testis | 8 | 2012 | 151 | 0.960 |
Why?
| | Spermatozoa | 5 | 2007 | 94 | 0.890 |
Why?
| | Varicocele | 7 | 2011 | 10 | 0.890 |
Why?
| | Prostatic Neoplasms | 14 | 2012 | 1043 | 0.750 |
Why?
| | Oligospermia | 5 | 2013 | 8 | 0.690 |
Why?
| | Azoospermia | 3 | 2013 | 6 | 0.640 |
Why?
| | Vas Deferens | 3 | 2006 | 12 | 0.520 |
Why?
| | Reproduction | 3 | 2006 | 204 | 0.500 |
Why?
| | Sperm Count | 5 | 2004 | 19 | 0.490 |
Why?
| | Urology | 3 | 2019 | 63 | 0.450 |
Why?
| | Hypogonadism | 3 | 2013 | 92 | 0.440 |
Why?
| | Penis | 3 | 2012 | 36 | 0.440 |
Why?
| | Clomiphene | 1 | 2013 | 15 | 0.420 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2013 | 29 | 0.410 |
Why?
| | Erectile Dysfunction | 3 | 2012 | 39 | 0.370 |
Why?
| | Diphosphonates | 1 | 2011 | 66 | 0.350 |
Why?
| | Male | 58 | 2021 | 67762 | 0.350 |
Why?
| | Testosterone | 3 | 2013 | 409 | 0.350 |
Why?
| | Oxalates | 4 | 2012 | 10 | 0.330 |
Why?
| | Apoptosis | 3 | 2004 | 2553 | 0.330 |
Why?
| | Fertility | 2 | 2006 | 160 | 0.330 |
Why?
| | Testicular Neoplasms | 3 | 2006 | 110 | 0.310 |
Why?
| | Ejaculatory Ducts | 4 | 2005 | 4 | 0.310 |
Why?
| | Electric Stimulation | 3 | 2005 | 264 | 0.310 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 740 | 0.300 |
Why?
| | Urinary Bladder | 3 | 2019 | 183 | 0.300 |
Why?
| | Genetic Therapy | 2 | 2008 | 297 | 0.300 |
Why?
| | Potassium Channels, Tandem Pore Domain | 2 | 2019 | 14 | 0.290 |
Why?
| | Autonomic Dysreflexia | 1 | 2007 | 4 | 0.280 |
Why?
| | Physical Stimulation | 1 | 2007 | 65 | 0.270 |
Why?
| | Prostate | 1 | 2008 | 175 | 0.270 |
Why?
| | Spermatogenesis | 4 | 2002 | 67 | 0.270 |
Why?
| | Vibration | 1 | 2007 | 72 | 0.270 |
Why?
| | Perineum | 1 | 2006 | 32 | 0.260 |
Why?
| | Penile Induration | 1 | 2006 | 2 | 0.260 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 2129 | 0.260 |
Why?
| | Vasovasostomy | 1 | 2006 | 1 | 0.260 |
Why?
| | Inguinal Canal | 1 | 2006 | 10 | 0.250 |
Why?
| | Hernia, Inguinal | 2 | 2006 | 36 | 0.250 |
Why?
| | Genital Diseases, Male | 2 | 1996 | 17 | 0.250 |
Why?
| | Semen Preservation | 2 | 2004 | 3 | 0.250 |
Why?
| | Humans | 64 | 2022 | 137585 | 0.250 |
Why?
| | Semen | 3 | 2002 | 18 | 0.250 |
Why?
| | Health Expenditures | 1 | 2007 | 189 | 0.240 |
Why?
| | Interferon-alpha | 1 | 2006 | 198 | 0.230 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 167 | 0.230 |
Why?
| | Anal Canal | 1 | 2005 | 97 | 0.230 |
Why?
| | Cost of Illness | 1 | 2007 | 308 | 0.230 |
Why?
| | Cloning, Organism | 1 | 2004 | 6 | 0.220 |
Why?
| | Aging | 5 | 2013 | 1864 | 0.220 |
Why?
| | Bioethical Issues | 1 | 2004 | 8 | 0.220 |
Why?
| | Cryptorchidism | 1 | 2004 | 15 | 0.220 |
Why?
| | Psychology, Adolescent | 1 | 2004 | 66 | 0.220 |
Why?
| | Spinal Cord Injuries | 1 | 2007 | 212 | 0.210 |
Why?
| | Vasectomy | 1 | 2003 | 1 | 0.210 |
Why?
| | Tissue and Organ Harvesting | 1 | 2003 | 70 | 0.200 |
Why?
| | Pain Management | 1 | 2006 | 352 | 0.200 |
Why?
| | Matrix Metalloproteinase 9 | 4 | 2012 | 132 | 0.200 |
Why?
| | Sperm Motility | 3 | 1998 | 32 | 0.200 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2003 | 34 | 0.200 |
Why?
| | Surgical Mesh | 1 | 2002 | 47 | 0.190 |
Why?
| | Cryopreservation | 2 | 2004 | 100 | 0.190 |
Why?
| | Epithelial Cells | 5 | 2012 | 1096 | 0.190 |
Why?
| | Kidney Medulla | 3 | 2008 | 35 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-ets | 2 | 2012 | 56 | 0.180 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 560 | 0.170 |
Why?
| | Checklist | 1 | 2021 | 93 | 0.170 |
Why?
| | Interdisciplinary Communication | 1 | 2021 | 191 | 0.170 |
Why?
| | Operating Rooms | 1 | 2021 | 123 | 0.160 |
Why?
| | Cysts | 3 | 1995 | 113 | 0.160 |
Why?
| | Kidney Tubules, Proximal | 2 | 2012 | 128 | 0.160 |
Why?
| | Inflammation | 1 | 2010 | 2837 | 0.160 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 30 | 0.150 |
Why?
| | Urination | 1 | 2019 | 45 | 0.150 |
Why?
| | Hormone Replacement Therapy | 2 | 2013 | 100 | 0.150 |
Why?
| | Nephrectomy | 1 | 2019 | 169 | 0.150 |
Why?
| | Cell Survival | 4 | 2011 | 1120 | 0.150 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 283 | 0.140 |
Why?
| | Priapism | 1 | 1998 | 11 | 0.140 |
Why?
| | Administration, Intravesical | 1 | 2017 | 15 | 0.140 |
Why?
| | Patient Safety | 1 | 2021 | 314 | 0.140 |
Why?
| | Patient Care Team | 2 | 2021 | 631 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2011 | 252 | 0.140 |
Why?
| | General Surgery | 1 | 2019 | 173 | 0.140 |
Why?
| | Urethra | 1 | 2017 | 55 | 0.140 |
Why?
| | Neoplasm Invasiveness | 4 | 2012 | 510 | 0.140 |
Why?
| | Specimen Handling | 1 | 1998 | 183 | 0.130 |
Why?
| | Urinary Bladder, Overactive | 1 | 2017 | 22 | 0.130 |
Why?
| | Constriction, Pathologic | 4 | 2005 | 245 | 0.130 |
Why?
| | Kidney Tubules, Collecting | 2 | 2008 | 31 | 0.130 |
Why?
| | Adult | 17 | 2022 | 37929 | 0.130 |
Why?
| | Cell Line, Tumor | 8 | 2012 | 3412 | 0.130 |
Why?
| | Computer Communication Networks | 1 | 1996 | 33 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 152 | 0.130 |
Why?
| | Muscle Contraction | 1 | 2019 | 424 | 0.120 |
Why?
| | Animals | 15 | 2019 | 36940 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 3 | 2008 | 185 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 306 | 0.120 |
Why?
| | Internship and Residency | 2 | 2019 | 1147 | 0.120 |
Why?
| | Temperature | 1 | 1998 | 679 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2002 | 758 | 0.120 |
Why?
| | Cannabinoids | 1 | 2017 | 161 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2022 | 515 | 0.110 |
Why?
| | Microsurgery | 2 | 2005 | 75 | 0.110 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1000 | 0.110 |
Why?
| | Drug Synergism | 2 | 2011 | 382 | 0.110 |
Why?
| | Marijuana Use | 1 | 2017 | 206 | 0.110 |
Why?
| | Asthenozoospermia | 1 | 2013 | 2 | 0.110 |
Why?
| | Imidazoles | 2 | 2011 | 238 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 4 | 2012 | 2486 | 0.100 |
Why?
| | Hyperoxaluria | 1 | 2012 | 3 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 26 | 0.100 |
Why?
| | Receptors, Virus | 1 | 2012 | 83 | 0.100 |
Why?
| | Rats | 5 | 2012 | 5647 | 0.090 |
Why?
| | Metalloporphyrins | 1 | 2012 | 103 | 0.090 |
Why?
| | Reproductive Techniques | 1 | 1991 | 5 | 0.090 |
Why?
| | Mitomycin | 1 | 2011 | 34 | 0.090 |
Why?
| | Valproic Acid | 1 | 2011 | 48 | 0.090 |
Why?
| | Radiotherapy | 1 | 2012 | 201 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1101 | 0.090 |
Why?
| | Osteoclasts | 1 | 2011 | 52 | 0.090 |
Why?
| | Cell Adhesion Molecules | 1 | 2012 | 181 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 71 | 0.090 |
Why?
| | Cell Hypoxia | 2 | 2009 | 226 | 0.090 |
Why?
| | Bone Resorption | 1 | 2011 | 86 | 0.090 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2011 | 127 | 0.090 |
Why?
| | Diabetes Complications | 2 | 2006 | 227 | 0.090 |
Why?
| | Patient Care Management | 1 | 2011 | 57 | 0.090 |
Why?
| | Laparoscopy | 2 | 2006 | 466 | 0.090 |
Why?
| | Cell Movement | 2 | 2012 | 967 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 310 | 0.080 |
Why?
| | Androgens | 2 | 2009 | 187 | 0.080 |
Why?
| | Atrophy | 1 | 2010 | 184 | 0.080 |
Why?
| | Resistance Training | 1 | 2013 | 164 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 210 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 500 | 0.080 |
Why?
| | Neoplasm Seeding | 1 | 1989 | 7 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 301 | 0.080 |
Why?
| | Up-Regulation | 1 | 2012 | 843 | 0.080 |
Why?
| | Transfection | 2 | 2010 | 945 | 0.080 |
Why?
| | Prostatectomy | 1 | 1989 | 104 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 1989 | 189 | 0.080 |
Why?
| | Bone Neoplasms | 1 | 2011 | 247 | 0.080 |
Why?
| | Antioxidants | 1 | 2012 | 584 | 0.070 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 34 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 284 | 0.070 |
Why?
| | Bone and Bones | 1 | 2011 | 317 | 0.070 |
Why?
| | Prostatic Hyperplasia | 1 | 2008 | 44 | 0.070 |
Why?
| | Biopsy | 1 | 1992 | 1129 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 622 | 0.070 |
Why?
| | Patient Selection | 1 | 2011 | 696 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2008 | 73 | 0.070 |
Why?
| | Bone Density | 1 | 2011 | 489 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 1050 | 0.070 |
Why?
| | Ultrasonography | 4 | 1995 | 759 | 0.070 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2007 | 37 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 278 | 0.070 |
Why?
| | Carcinoma in Situ | 1 | 2006 | 49 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 455 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2010 | 1317 | 0.060 |
Why?
| | Computer Simulation | 1 | 2011 | 978 | 0.060 |
Why?
| | Acupuncture Therapy | 1 | 2006 | 21 | 0.060 |
Why?
| | Injections, Intralesional | 1 | 2006 | 34 | 0.060 |
Why?
| | Cell Line | 5 | 2012 | 2847 | 0.060 |
Why?
| | Health Resources | 1 | 2007 | 120 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 1988 | 258 | 0.060 |
Why?
| | Biomarkers | 1 | 2017 | 4149 | 0.060 |
Why?
| | Software | 1 | 2011 | 665 | 0.060 |
Why?
| | Anus, Imperforate | 1 | 2005 | 24 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 142 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1477 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 363 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2006 | 153 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2607 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1774 | 0.060 |
Why?
| | Incidence | 2 | 2007 | 2804 | 0.060 |
Why?
| | Oxalic Acid | 1 | 2004 | 4 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 545 | 0.060 |
Why?
| | Kidney | 1 | 2012 | 1468 | 0.060 |
Why?
| | Rupture | 1 | 2004 | 92 | 0.060 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 64 | 0.060 |
Why?
| | Seminiferous Tubules | 1 | 2004 | 13 | 0.060 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2003 | 8 | 0.050 |
Why?
| | Signal Transduction | 3 | 2012 | 5079 | 0.050 |
Why?
| | Andrology | 1 | 2003 | 2 | 0.050 |
Why?
| | Female | 9 | 2021 | 73304 | 0.050 |
Why?
| | Hypoxia | 1 | 2010 | 1112 | 0.050 |
Why?
| | Sex Counseling | 1 | 2003 | 4 | 0.050 |
Why?
| | Middle Aged | 7 | 2007 | 33479 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2007 | 546 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1353 | 0.050 |
Why?
| | Down-Regulation | 2 | 2017 | 657 | 0.050 |
Why?
| | Iatrogenic Disease | 1 | 2002 | 67 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 1988 | 940 | 0.040 |
Why?
| | Pain | 1 | 2006 | 756 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2017 | 622 | 0.040 |
Why?
| | Adolescent | 4 | 2007 | 21513 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2004 | 778 | 0.040 |
Why?
| | Phenotype | 4 | 2010 | 3196 | 0.040 |
Why?
| | Aged | 6 | 2013 | 23961 | 0.040 |
Why?
| | Organizational Culture | 1 | 2021 | 148 | 0.040 |
Why?
| | Counseling | 1 | 2003 | 391 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 2022 | 265 | 0.040 |
Why?
| | Alcoholism | 1 | 2006 | 807 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2007 | 7635 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 83 | 0.040 |
Why?
| | Sexual Behavior | 2 | 1994 | 485 | 0.040 |
Why?
| | Cell Growth Processes | 2 | 2010 | 52 | 0.040 |
Why?
| | Cell Count | 2 | 2005 | 324 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2253 | 0.040 |
Why?
| | Mice | 5 | 2019 | 17787 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2012 | 2833 | 0.040 |
Why?
| | Risk Factors | 3 | 2002 | 10388 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2022 | 556 | 0.040 |
Why?
| | Caveolins | 1 | 2017 | 6 | 0.030 |
Why?
| | DNA Replication | 2 | 2004 | 238 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5757 | 0.030 |
Why?
| | Hospitalization | 1 | 2007 | 2199 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1738 | 0.030 |
Why?
| | DNA Primers | 2 | 2010 | 515 | 0.030 |
Why?
| | United States | 2 | 2019 | 14841 | 0.030 |
Why?
| | Blotting, Western | 2 | 2010 | 1226 | 0.030 |
Why?
| | Prostatic Diseases | 1 | 1995 | 4 | 0.030 |
Why?
| | Seminal Vesicles | 1 | 1995 | 10 | 0.030 |
Why?
| | Mullerian Ducts | 1 | 1995 | 12 | 0.030 |
Why?
| | Cytoskeleton | 1 | 2017 | 191 | 0.030 |
Why?
| | Arteries | 1 | 1998 | 269 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 1998 | 474 | 0.030 |
Why?
| | International Cooperation | 1 | 1996 | 198 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2011 | 15657 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 433 | 0.030 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2017 | 261 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 486 | 0.030 |
Why?
| | Paternal Age | 1 | 1994 | 3 | 0.030 |
Why?
| | Climacteric | 1 | 1994 | 4 | 0.030 |
Why?
| | Skin | 2 | 2012 | 752 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5778 | 0.030 |
Why?
| | Diverticulum | 1 | 1994 | 12 | 0.030 |
Why?
| | Rectum | 1 | 1995 | 185 | 0.030 |
Why?
| | Chromosome Disorders | 1 | 1994 | 43 | 0.030 |
Why?
| | Color | 1 | 1994 | 76 | 0.030 |
Why?
| | Urethral Diseases | 1 | 1994 | 19 | 0.030 |
Why?
| | Base Sequence | 2 | 2010 | 2181 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2005 | 6079 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 1994 | 156 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2022 | 1313 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 19 | 0.030 |
Why?
| | Leydig Cells | 1 | 1993 | 15 | 0.030 |
Why?
| | Gonadotropins, Pituitary | 1 | 1993 | 22 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 1994 | 530 | 0.030 |
Why?
| | Sertoli Cells | 1 | 1993 | 26 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2013 | 59 | 0.020 |
Why?
| | Gene Expression | 2 | 2008 | 1502 | 0.020 |
Why?
| | Physical Examination | 1 | 1994 | 241 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1178 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2012 | 42 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 67 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 24 | 0.020 |
Why?
| | Sex Chromosome Aberrations | 1 | 1993 | 64 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2012 | 80 | 0.020 |
Why?
| | Crystallization | 1 | 2012 | 143 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3015 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1710 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 194 | 0.020 |
Why?
| | Upper Extremity | 1 | 2013 | 99 | 0.020 |
Why?
| | Insemination, Artificial | 1 | 1991 | 10 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 257 | 0.020 |
Why?
| | Kidney Tubules | 1 | 2012 | 117 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1995 | 1483 | 0.020 |
Why?
| | Menopause | 1 | 1994 | 320 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 224 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 455 | 0.020 |
Why?
| | Fertilization in Vitro | 1 | 1991 | 83 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 283 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 499 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 99 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1111 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 698 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 209 | 0.020 |
Why?
| | Muscle Strength | 1 | 2013 | 317 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 861 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1236 | 0.020 |
Why?
| | Actuarial Analysis | 1 | 1989 | 27 | 0.020 |
Why?
| | Radiotherapy, High-Energy | 1 | 1989 | 17 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 955 | 0.020 |
Why?
| | DNA Damage | 1 | 2012 | 420 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 658 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2013 | 413 | 0.020 |
Why?
| | Workload | 1 | 2011 | 167 | 0.020 |
Why?
| | Safety | 1 | 2011 | 338 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 684 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 34 | 0.020 |
Why?
| | Patient Compliance | 1 | 2013 | 581 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 1994 | 2031 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1066 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 2057 | 0.020 |
Why?
| | Brachytherapy | 1 | 1989 | 121 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1989 | 307 | 0.020 |
Why?
| | Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) | 1 | 2008 | 8 | 0.020 |
Why?
| | Penile Erection | 1 | 2008 | 7 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 21 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 1989 | 352 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2008 | 72 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 2008 | 171 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 55 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2008 | 113 | 0.020 |
Why?
| | Culture Media | 1 | 2008 | 165 | 0.020 |
Why?
| | Ureter | 1 | 1988 | 36 | 0.020 |
Why?
| | Kidney Calculi | 1 | 1988 | 38 | 0.020 |
Why?
| | Lithotripsy | 1 | 1988 | 48 | 0.020 |
Why?
| | Superoxides | 1 | 2008 | 202 | 0.020 |
Why?
| | Catheters, Indwelling | 1 | 1988 | 91 | 0.020 |
Why?
| | Cyclooxygenase 2 | 1 | 2008 | 178 | 0.020 |
Why?
| | Prevalence | 1 | 1994 | 2734 | 0.020 |
Why?
| | Regression Analysis | 1 | 1989 | 1024 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 810 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 139 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2008 | 319 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2008 | 466 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 320 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2008 | 328 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1396 | 0.020 |
Why?
| | Pyridines | 1 | 2010 | 506 | 0.020 |
Why?
| | Models, Animal | 1 | 2008 | 384 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 259 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1457 | 0.020 |
Why?
| | Swine | 1 | 2008 | 775 | 0.010 |
Why?
| | Research Design | 1 | 2011 | 1139 | 0.010 |
Why?
| | Models, Biological | 1 | 2012 | 1783 | 0.010 |
Why?
| | Cell Cycle | 1 | 2008 | 601 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2828 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1062 | 0.010 |
Why?
| | Testicular Hydrocele | 1 | 2004 | 4 | 0.010 |
Why?
| | Urinary Retention | 1 | 2004 | 21 | 0.010 |
Why?
| | Ligation | 1 | 2004 | 92 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2006 | 218 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1719 | 0.010 |
Why?
| | Veins | 1 | 2004 | 63 | 0.010 |
Why?
| | Pregnancy | 2 | 1997 | 6763 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1759 | 0.010 |
Why?
| | Algorithms | 1 | 2011 | 1704 | 0.010 |
Why?
| | Carcinoma | 1 | 1986 | 240 | 0.010 |
Why?
| | Hospital Costs | 1 | 2004 | 117 | 0.010 |
Why?
| | Prognosis | 2 | 1989 | 4030 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3284 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2008 | 10811 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2475 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2111 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1040 | 0.010 |
Why?
| | Time Factors | 1 | 1989 | 6828 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2005 | 4193 | 0.010 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 1994 | 39 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2004 | 2654 | 0.010 |
Why?
| | Calcinosis | 1 | 1992 | 235 | 0.010 |
Why?
| | Silicones | 1 | 1988 | 25 | 0.000 |
Why?
| | Urinary Catheterization | 1 | 1988 | 33 | 0.000 |
Why?
| | Ureteral Obstruction | 1 | 1988 | 64 | 0.000 |
Why?
| | Child | 1 | 2004 | 21935 | 0.000 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1986 | 1079 | 0.000 |
Why?
|
|
Meacham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|